Impact of denosumab on muscle health in older adults in long-term care.

ABSTRACT:

Background

Osteosarcopenia, a condition characterized by the simultaneous presence of osteoporosis and sarcopenia, is a common geriatric syndrome associated with increased risk of falls and fracture. While there are multiple medications available for the management of osteoporosis, there are currently no approved pharmacological treatments for sarcopenia.

Methods

In this secondary analysis of a 2-year, double-blind, placebo-controlled, randomized trial involving 201 men and women with osteoporosis aged ≥65 years who were residents of long-term care communities (LTCCs), we examined the impact of denosumab on various indices of muscle health. Study participants received either denosumab 60 mg every 6 months or a matching placebo. We measured appendicular lean mass (ALM/Height<

SUBMITTER: Haeri NS 

PROVIDER: S-EPMC12683716 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature